Loading
Charles River Laboratories International, Inc. Stock: price and insider trades · United States
1 insider bought €2,622 of shares over the last 90 days, the latest filed 02 Oct 2026.
Charles River Laboratories International, Inc.: what insiders have been doing
This page follows insider dealings at Charles River Laboratories International, Inc. as filed with SEC (Form 4), a company from the Healthcare & Pharma sector based in Wilmington, United States. The group dates from 1947. The last twelve months, up to 18 October 2026, brought 98 filings signed by 16 insiders.
The record shows 2 purchases on the open market worth €6,352, made by 2 insiders, against 15 sales worth €11.5M by 6 insiders. No amount is published for 1 filing, which the totals therefore leave out. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. Biggest ticket of the year: €8.6M, sold by Foster James C and made public on 27 August 2026 (0.074% of market cap). Those buying include 1 finance chief and 1 senior executive.
Across the 5,458 companies tracked on its exchange, the median is 22 filings; at 98 filings, this issuer sits above that mark. Our records for Charles River Laboratories International, Inc. go back to 2016, with 8 purchases and 55 sales on the open market in total. In its latest annual report filed with the SEC (10-K, fiscal year ended 27 December 2025), the company reported revenue of 4.02 bn USD and net income of -144.3 m USD.
The last insider purchase was made public on 2 October 2026, 16 days ago. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 3 days. The legal deadline for a Form 4 is two business days after the transaction. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning.
Elsewhere in the same sector, our signals recently picked up insider purchases at Anixa Biosciences Inc and Vivos Inc. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Insider Decl.
370
Thresholds
n/a
Buy Volume
€3M
8 ops. · all time
Sell Volume
€33M
55 ops. · all time
Who traded when
BuySaleMichael Gunnar Knell9 sales
Joseph W. LaPlume1 buy5 sales
James C. Foster1 buy2 sales
Massaro George2 sales
Birgit Girshick1 buy
Glenn Coleman1 buy
+3 other insiders
Since the insiders bought
- -0.8%Entry US$181.32 · Close at T+90 US$179.87
- -4.1%Entry US$170.51 · Close at T+365 US$163.52
- -4.1%Entry US$170.51 · Close at T+365 US$163.52
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Charles River Laboratories International, Inc. Buy (bullish), based on 14 analysts. Average price target: US$301.29.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 20,171 of 24,148 companies
28.0
score / 100
Value31
Quality25
FCF yld3.7%
Earn yld-1.0%
EV/EBITDA40.5x
ROE-7.5%
Gross mgn33%
Net mgn-3.6%
Debt/EBITDA6.3x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$294.59
Analyst consensus
14 analystsBuy
US$145.00Target US$301.29(+2%)US$340.00
Income statement
RevenueUS$4B
Gross profitUS$1.3B33% margin
EBITDAUS$410.8M10% margin
Net income-US$144.3M-6.0% margin
Valuation
PER (forward)23.2x
P/Book5.0x
Beta1.41
Balance sheet & cash
Market capUS$14.1B
Total debtUS$2.6B
Free Cash FlowUS$518.5M
Debt / Equity105%
Profitability & ownership
ROE-7.5%
ROA4.1%
% insiders0.5%
% institutions123.7%
Last declaration on 7 October 2026
Declarations370 total
981 shares@ US$208.440.0014% mcap2.5% of flowCommon StockSEC:0001952784-26-000003:0
981 shares@ US$308.440.0021% mcap3.7% of flowCommon StockSEC:0001952784-26-000003:1
981 shares@ US$314.55620.0022% mcap19.3% of flowCommonSEC144:0001969223-26-001063
10 shares@ US$297.430.0000% mcap0.3% of flowCommon StockSEC:0001100682-26-000144:0
Canonical exit: 29 Dec 2026 (T+90)
21,132 shares@ US$194.120.030% mcap15.3% of flowCommon StockSEC:0001100682-26-000140:0
12,429 shares@ US$208.440.019% mcap9.7% of flowCommon StockSEC:0001100682-26-000140:1
33,561 shares@ US$300.000.074% mcap37.5% of flowCommon StockSEC:0001100682-26-000140:2
33,561 shares@ US$299.930.074% mcap37.5% of flowCommonSEC144:0001969223-26-000955
573 shares@ US$164.300.0007% mcap17.9% of flowCommon StockSEC:0001100682-26-000134:0
573 shares@ US$285.240.0011% mcap31.1% of flowCommon StockSEC:0001100682-26-000134:1
2,039 shares@ US$194.120.0028% mcap5.1% of flowCommon StockSEC:0001100682-26-000136:0
528 shares0Common StockSEC:0001100682-26-000138:0
2,039 shares@ US$294.120.0042% mcap7.7% of flowCommonSEC144:0001969223-26-000932
573 shares@ US$285.000.0012% mcap100.0% of flowCommon StockSEC144:0001969223-26-000918
3,714 shares@ US$179.660.0047% mcap8.6% of flowCommon StockSEC:0001100682-26-000130:0
6,500 shares@ US$179.660.0082% mcap11.5% of flowCommon StockSEC:0001100682-26-000132:0
3,714 shares@ US$279.660.0073% mcap13.4% of flowCommonSEC144:0001969223-26-000886
6,500 shares@ US$279.900.013% mcap17.9% of flowCommonSEC144:0001969223-26-000885
257 shares0Common StockSEC:0001100682-26-000128:0
28,733 shares@ US$179.660.036% mcap8.6% of flowCommon StockSEC:0001100682-26-000126:0
28,733 shares@ US$275.000.056% mcap13.2% of flowCommonSEC144:0001969223-26-000874
736 shares@ US$208.440.0011% mcap3.4% of flowCommon StockSEC:0001100682-26-000124:8
4,179 shares@ US$179.660.0053% mcap12.1% of flowCommon StockSEC:0001100682-26-000122:0
4,179 shares@ US$259.160.0076% mcap17.4% of flowCommon StockSEC:0001100682-26-000122:1
1,274 shares@ US$259.070.0023% mcap7.2% of flowCommon StockSEC:0001100682-26-000124:0
25 of 370 declarations
About Charles River Laboratories International, Inc.
Charles River Laboratories International, Inc. (ticker: CRL) is a U.S.-based company listed on the NYSE (New York Stock Exchange) in the United States. For French-, Belgian- and Swiss-based investors, it represents a core life-sciences services and tools business, positioned early in the pharmaceutical value chain and therefore leveraged to R&D spending by pharma companies, biotech firms, government agencies, and academic institutions. The company traces its origins to 1947, when it began as a one-person laboratory in Boston overlooking the Charles River. Its headquarters was later relocated to Wilmington, Massachusetts, where it remains today, and the group has evolved into a global strategic partner supporting discovery, early development, and certain manufacturing activities. ([criver.com](https://www.criver.com/about-us/about-us-overview/our-story?utm_source=openai))
Charles River’s business model is built around several complementary operating lines. Research Models and Services provides laboratory animal models, including rodent models, together with related services that support basic and translational research. Discovery and Safety Assessment offers preclinical services such as pharmacology, toxicology, pathology, safety assessment, and regulatory support. The company also has manufacturing- and insourcing-oriented capabilities, supporting biologics and development workflows; however, in 2026 it announced a definitive agreement to divest its CDMO and Cell Solutions businesses, indicating a sharper strategic focus on its higher-value scientific platforms. Overall, the company is positioned as an integrated early-stage drug development partner rather than a pure-play CRO or a standalone laboratory-animal supplier. ([ir.criver.com](https://ir.criver.com/news-releases/news-release-details/charles-river-laboratories-announces-third-quarter-2025-results?utm_source=openai))
Read moreShow less
From a competitive standpoint, Charles River benefits from deep scientific expertise, a long operating history, and a broad international footprint. The company says it operates more than 130 facilities across 30 countries, giving it reach across North America, Europe, and Asia and allowing it to serve global pharmaceutical and biotech clients with local execution. That scale, combined with its breadth across discovery, preclinical safety, and research models, supports its relevance in a highly fragmented but quality-sensitive market. ([criver.com](https://www.criver.com/about-us/about-us-overview/our-story?utm_source=openai))
Recent developments matter for the investment case. In February 2026, Charles River reported full-year 2025 revenue of $4.02 billion, slightly below the prior year, while highlighting improved non-GAAP margin performance driven by restructuring and cost actions. In May 2026, the company announced continued momentum in its digital pathology platform, describing an AI-enabled end-to-end workflow designed to shorten study timelines and improve pathologist efficiency. Management has also been actively reshaping the portfolio, as shown by the planned divestiture of the CDMO and Cell Solutions businesses to GI Partners. These moves suggest a management team focused on simplification, margin discipline, and concentration on differentiated science. ([ir.criver.com](https://ir.criver.com/news-releases/news-release-details/charles-river-laboratories-announces-fourth-quarter-and-full-14/?utm_source=openai))
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
